Answers are grounded in this paper and cite their sources.
Background Hepatitis B virus (HBV) remains an immense global health challenge. Despite the availability of antiviral therapies, no curative treatment exists. Only a small proportion of individuals with chronic hepatitis B (CHB) achieve a functional cure. Resistance and vaccine escape mutations (EMs) may compromise current nucleos(t)ide analogs, vaccines and emerging therapies, leading to treatment failure. The present study aimed to assess the frequency of these HBV mutations in >17,000 publicly available patient-derived HBV sequences. Methods Fold-change (FC) data and resistance/escape-associated mutations were retrieved from literature searches. HBV sequences were retrieved from the NCBI Nucleotide and NCBI Virus databases. Human HBV isolates were genotyped using the HBVdb and Stanford HBVseq tools and GenBank data. Genotype-specific alignments were generated using MAFFT v7 and mutations were analyzed across reverse transcriptase (RT), core (C), surface (S) and X regions using in-house Python scripts. Results From 19,192 sequence identifiers retrieved, 17,012 genotyped sequences were analyzed. Genotypes C, B, D and A comprised approximately 85% of the dataset. RT-mutations, L180M + M204V and M204I, were frequent in certain genotypes like A, G, H, AG, and G, respectively. C-mutations, Y38F, I105T, and T109M, were identified in common genotypes. In the S-protein, G145R, E164G, and E164D mutations were the most common and these mutations are known to alter the effectiveness of monoclonal antibodies (mAbs). In general, S-mutations toward the studied mAbs occurred at low-to-moderate frequency. Some substitutions previously suggested to be vaccine escape-associated mutations were highly prevalent, however, these substitutions may be polymorphisms specific to certain genotypes requiring further validation. X-region mutations relevant for treatment based on antisense oligonucleotides (ASOs) were uncommon overall. Conclusion HBV isolates with resistance and vaccine escape-associated mutations are present globally and might be genotype-dependent. Therefore, genotype and resistance assessment are crucial before initiating therapy for a favorable outcome in patients, especially when new drugs are introduced to achieve functional cure.
No takes yet. Share an insight, caveat, or question.
Anandasaravanan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: